Literature DB >> 12427208

A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections.

Roger G Finch1, D E Low.   

Abstract

Guidelines are an important means by which professional associations and governments have sought to improve the quality and cost-effectiveness of disease management for infectious diseases. Prescribing of initial antibiotic therapy for community-acquired respiratory tract infections (RTIs) is primarily empiric and physicians may often have a limited appreciation of bacterial resistance. Recent guidelines for managing RTIs have adopted a more evidence-based approach. This process has highlighted important gaps in the existing knowledge base, e.g. concerning the impact of resistance on the effectiveness of oral antibiotics for outpatient community-acquired pneumonia and the level of resistance that should prompt a change in empiric prescribing. In upper RTIs, the challenge is to identify patients in whom antibiotic therapy is warranted. Concentrated, sustained efforts are needed to secure physicians' use of guidelines. The information should be distilled into a simple format available at the point of prescribing and supported by other behavioral change techniques (e.g. educational outreach visits). Advances in information technology offer the promise of more dynamic, computer-assisted forms of guidance. Thus, RTI prescribing guidelines and other prescribing support systems should help control bacterial resistance in the community. However, their effect on resistance patterns is largely unknown and there is an urgent need for collaborative research in this area. Rapid, cost-effective diagnostic techniques are also required and new antibiotics will continue to have a role in disease management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427208     DOI: 10.1046/j.1469-0691.8.s.2.7.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.

Authors:  T M File; H Lode; H Kurz; R Kozak; H Xie; E Berkowitz
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 2.  Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?

Authors:  Patricia D Brown
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Medicaid/State Children's Health Insurance Program patients and infectious diseases treated in emergency departments: U.S., 2003.

Authors:  Nelson Adekoya
Journal:  Public Health Rep       Date:  2007 Jul-Aug       Impact factor: 2.792

4.  Revolutionizing clinical microbiology laboratory organization in hospitals with in situ point-of-care.

Authors:  Stéphan Cohen-Bacrie; Laetitia Ninove; Antoine Nougairède; Rémi Charrel; Hervé Richet; Philippe Minodier; Sékéné Badiaga; Guilhem Noël; Bernard La Scola; Xavier de Lamballerie; Michel Drancourt; Didier Raoult
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

5.  The state of play in the battle against antimicrobial resistance: a general practitioner perspective.

Authors:  Douglas M Fleming
Journal:  J Antimicrob Chemother       Date:  2007-08       Impact factor: 5.790

6.  Long-term effect of computer-assisted decision support for antibiotic treatment in critically ill patients: a prospective 'before/after' cohort study.

Authors:  I Nachtigall; S Tafelski; M Deja; E Halle; M C Grebe; A Tamarkin; A Rothbart; A Uhrig; E Meyer; L Musial-Bright; K D Wernecke; C Spies
Journal:  BMJ Open       Date:  2014-12-22       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.